Acquisitions (Tables)

12 Months Ended

Dec. 31, 2020

Rave

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

Consideration Transferred:
Cash paid	$	55.8
Contingent consideration		4.4
Working capital adjustment		(3.6)
Total consideration transferred	$	56.6
Allocation of Consideration Transferred:
Inventories	$	23.1
Accounts receivable		2.2
Other current and non current assets		0.8
Property, plant and equipment		2.1
Operating lease assets		1.0
Intangible assets:
Technology		17.9
Customer relationships		15.5
Trade name		1.5
Goodwill		6.4
Liabilities assumed		(13.9)
Total consideration transferred	$	56.6

Canopy Biosciences

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

Consideration Transferred:
Cash paid	$	24.4
Contingent consideration		0.5
Cash acquired		(0.5)
Working capital adjustment		0.3
Total consideration transferred	$	24.7
Allocation of Consideration Transferred:
Inventories	$	1.1
Accounts receivable		1.2
Other current and non-current assets		1.0
Property, plant and equipment		0.9
Operating lease assets		0.3
Intangible assets:
Technology		5.7
Customer relationships		6.1
Trade name		0.7
Backlog		0.3
Goodwill		12.0
Deferred taxes, net		(2.0)
Liabilities assumed		(2.6)
Total consideration allocated	$	24.7

2019 Acquisitions

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

Name of Acquisition	Date Acquired	Segment	Consideration		Cash Consideration
Arxspan, LLC	March 4, 2019	BSI Life Science	$	16.6	$	14.4
Ampegon PPT GmbH	March 7, 2019	BEST		2.0		2.0
PMOD Technologies GmbH	July 1, 2019	BSI Life Science		8.9		7.9
Magnettech GmbH	October 2, 2019	BSI Life Science		9.3		9.3
BioVendor Instruments a.s.	November 1, 2019	BSI Life Science		1.3		1.3
			$	38.1	$	34.9

2018 Acquisitions

Acquisitions

Schedule of consideration transferred and the respective reporting segment for each acquisition

	Anasys		JPK		Mestrelab		Hain		Alicona
					BSI		BSI
Segment	BSI NANO		BSI NANO		Life Science		Life Science		BSI NANO
Consideration Transferred:
Cash paid	$	27.0	$	16.6	$	11.2	$	76.6	$	55.4
Cash acquired		—		(0.2)		(1.9)		(3.4)		(1.4)
Contingent consideration		5.3		4.3		—		—		—
Total consideration transferred	$	32.3	$	20.7	$	9.3	$	73.2	$	54.0
Allocation of Consideration Transferred:
Inventories	$	2.8	$	3.0	$	—	$	9.7	$	10.1
Accounts receivable		0.8		1.8		2.4		5.9		3.7
Other current and non-current assets		1.1		0.7		0.8		1.5		2.0
Property, plant and equipment		—		—		0.1		2.3		1.5
Intangible assets:
Technology		7.3		7.0		4.9		38.1		15.2
Customer relationship		8.0		7.5		4.7		38.6		19.8
Backlog		1.8		1.1		—		—		2.3
Trade name		0.6		0.6		0.5		3.9		1.9
Goodwill		16.6		8.0		12.5		42.3		19.3
Deferred taxes, net		(3.2)		(4.9)		(2.5)		(19.6)		(9.1)
Liabilities assumed		(3.5)		(4.1)		(1.3)		(15.0)		(6.5)
Assumed debt		—		—		—		(11.3)		(6.2)
Redeemable noncontrolling interest		—		—		—		(23.2)		—
Hybrid instrument liability		—		—		(12.8)		—		—
Total consideration transferred	$	32.3	$	20.7	$	9.3	$	73.2	$	54.0

2020 Acquisitions

Acquisitions

Schedule of Components and fair value allocation of the consideration transferred in connection with acquisitions

				Total		Cash
Name of Acquisition	Date Acquired		Segment	Consideration		Consideration
SmartTip B.V.		April 1, 2020	BSI Nano	$	3.1	$	2.4
Integrated Proteomics Applications, Inc.		August 7, 2020	BSI Life Science		3.0		3.0
				$	6.1	$	5.4